Search
New Jersey Paid Clinical Trials
A listing of 1665 clinical trials in New Jersey actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1177 - 1188 of 1665
New Jersey is currently home to 1665 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Dose Reduction of Postoperative Radiation for Soft Tissue Sarcoma of the Arms and Legs
Recruiting
The investigators are doing this study to find out whether lowering the dose of postoperative radiation therapy and targeting a smaller area of tissue for treatment is as effective as the standard dose and volume of radiation therapy to control soft tissue sarcoma after surgery. They also want to find out whether the study approach causes fewer and less severe long-term side effects than the standard approach.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Memorial Sloan Kettering Basking Ridge (All protocol activities), Basking Ridge, New Jersey
Conditions: Soft Tissue Sarcoma
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
Recruiting
The purpose of this study is to find out whether the study drug, TSR-042, followed by standard chemoradiotherapy (the chemotherapy drug capecitabine + radiation therapy) and standard surgery is an effective treatment for advanced dMMR solid tumors. The study will also look at the safety of the study drug.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Memorial Sloan Kettering Basking Ridge - Limited Protocol Activities, Basking Ridge, New Jersey
Conditions: Rectal Adenocarcinoma, Clinical Stage: Stage II (T3-4, N-), Stage III (Any T, N+), Solid Tumor, Solid Tumor, Adult
R3THA Rehabilitation Feasibility and Usability Study
Recruiting
The purpose of this study is to assess how the Rehabilitation Technologies for Hand and Arm (R3THA) device can be used for rehabilitation of people with stroke. the study will evaluate the feasibility of R3THA as outpatient telerehabilitation administered by trained clinicians to individuals with stroke.
Gender:
ALL
Ages:
Between 20 years and 80 years
Trial Updated:
02/28/2025
Locations: Kessler Foundation, West Orange, New Jersey
Conditions: Stroke
A Study in the Treatment of Mild to Moderate Dry Eye Disease Comparing Saline to TTAX03.
Recruiting
The purpose of this randomized, controlled, multicenter study is to evaluate the safety and efficacy of TTAX03 in participants with mild to moderate DED.
The primary question it aims to answer is if TTAX03 is safe. The secondary is the effectiveness.
Researchers will compare 10mg of TTAX03 reconstituted in 150, 300, or 600 uL saline to the saline control group to look at effectiveness.
Participants will be randomized to a treatment group one time and be evaluated at 5 different study visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Eye Associates of North Jersey, Dover, New Jersey
Conditions: Dry Eye, Dry Eye Disease (DED), Dry Eye Disease With Severe Keratitis
Integrity Implant System Post Market Clinical Follow-Up Study
Recruiting
The study design is a prospective, multi-center, single-arm, non-randomized post market clinical follow-up study to confirm the performance, safety and clinical benefit of the Integrity Implant System when used for rotator cuff tear augmentation (with or without repair).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Virtua Health, Marlton, New Jersey
Conditions: Rotator Cuff Tears of the Shoulder
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. The study will last about 18 months
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Circuit Clinical/Mercer Allergy and Pulmonary Associates, Hamilton, New Jersey
Conditions: Perennial Allergic Rhinitis (PAR)
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
Recruiting
The goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the HR+, HER2-low (immunohistochemistry \[IHC\]2+/in situ hybridization \[ISH\]- and IHC 1+) population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Research Site 1111-0, Florham Park, New Jersey
Conditions: Metastatic Breast Cancer
Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections
Recruiting
A single dose infusion of Vabomere (meropenem-vaborbactam) is being tested for dose-finding, pharmacokinetics, safety, and tolerability in pediatric subjects from birth to less than 18 years of age with serious bacterial infections
Gender:
ALL
Ages:
17 years and below
Trial Updated:
02/27/2025
Locations: Rutger's University, New Brunswick, New Jersey
Conditions: Bacterial Infections
Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
Recruiting
GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of intravenous (IV) administration of GIM-122 in adults with advanced malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2025
Locations: Rutgers Cancer Institute of NJ, New Brunswick, New Jersey
Conditions: Advanced Solid Malignancies
Re-Connect Application for Smoking Cessation
Recruiting
This series of studies will explore the acceptability, feasibility, and preliminary efficacy of making access to smartphone applications contingent on objective evidence of smoking abstinence.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2025
Locations: Rowan University, Glassboro, New Jersey
Conditions: Smoking Cessation, Acceptability of Health Care, Nicotine Dependence, Cigarettes
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
Recruiting
The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.
Gender:
ALL
Ages:
All
Trial Updated:
02/26/2025
Locations: Clinical Research dep. Davison Place. Englewood Health, Englewood, New Jersey
Conditions: Brain Tumor, Recurrent, Brain Tumor, Brain Tumor, Primary, Brain Tumor - Metastatic, Brain Tumor, Adult: Glioblastoma, Brain Tumor, Adult Meningioma
Self-balancing Personal Exoskeleton for SCI (site 2)
Recruiting
This study aims to demonstrate the safety and effectiveness of the personal exoskeleton in individuals with spinal cord injury (SCI).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Kessler Foundation, West Orange, New Jersey
Conditions: Spinal Cord Injuries (SCI), Paraplegia and Tetraplegia